U.S. Backs Roche Cervical Cancer Test
April 26, 2011
The U.S. Food and Drug Administration has approved Roche Holding AG's new cobas human papillomavirus test, which can detect several high-risk strains of HPV, the firm recently announced. FDA supported the cobas HPV Test after reviewing its use in a clinical trial involving more than 47,000 women.
"The test is fully automated, has a high reliability and throughput rate," said Daniel O'Day, head of Roche's diagnostics division.
Wall Street Journal
04.20.2011; Goran Mijuk
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)